sodium-glucose co-transporter 2 inhibitors effects in failing heart patients

Conditions: Diabetes Mellitus; Heart Failure; Ventricular Arrythmia

Summary: slgt2 therapy is safety used in heart failure (hf) patients with depressed left ventricle ejection fraction (lvef) and diabetes mellitus (dm). these patients experience higher rate of ventricular arrhythmias (va), that are a leading cause of cardiac arrest and mortality. however, these patients are treated by implantable cardioverter defibrillator (icd) and cardiac resynchronization with defbrillator devices (crtd) implant. in this setting, the catheter ablation (ca) treatment has been used to reduce the ventricular arrhythmias and the icd/crtds' interventions, and to prevent mortality events in these' patients. on other hand, still a higher percentage of patients result as non responders to an ablative approach with higher acute and long term mortality rate. therefore, in the present study in a population of hf patients (dm vs. non dm patients) affected by va, authors will investigate the effects of ca on mortality rate at 12 months of follow up. in addition, authors would demonstrate the ameliorative effects of new hypoglycemic drugs in addition to ca in patients with dm. however, after ca the patients with dm will be randomly assigned to sglt2 therapy vs. placebo. indeed, study hypothesis will be that, a) dm vs. non dm patients might have higher mortality rate after ca; b) patients with dm treated by ca plus slgt2 therapy vs. patients with dm treated by ca plus placebo might experience a lower rate of mortality at 1 year of follow-up.

slgt2 therapy is safety used in heart failure (hf) patients with depressed left ventricle ejection fraction (lvef) and diabetes mellitus (dm). indeed, in these patients sglt2 therapy reduces hospital admission for heart failure and mortality rate. to date, these patients experience higher rate of ventricular arrhythmias (va), that are a leading cause of cardiac arrest and mortality. however, as indicated by international guidelines, these patients can be treated by implantable cardioverter defibrillator (icd) and crtd as primary and/or secondary prevention therapy. consequently, the effectiveness of icd and crtd is to treat sustained va, and to reduce cardiac arrest events and mortality. indeed, icds/crtds' anti-tachycardia pacing and shocks can interrupt va, and this might prevent a cardiac arrest event. this therapeutic effect can positively impact on acute and long term patients' survival. on other hand, authors showed that, continuous va events and icds' interventions are causes of reduced patients' life expectancy in hf patients. this worse prognosis is particularly evidenced in failing heart patients with dm as compared to patients without dm. in this setting, the catheter ablation (ca) treatment has been used to reduce the ventricular arrhythmias and the icds/crtds' interventions, and to prevent mortality events in these patients. on other hand, still a higher percentage of patients result as non responders to an ablative approach with higher acute and long term mortality rate. among these non responders patients to an ablative approach, dm is a negative prognostic factor. therefore, in the present study in a population of hf patients (dm vs. non dm patients) with va authors will investigate the effects of ca on mortality rate at 12 months of follow up. in addition, authors would like to demonstrate the ameliorative effects of new hypoglycemic drugs in addition to ca in patients with dm. however, after ca the patients with dm will be randomly assigned to sglt2 therapy vs. placebo. indeed, study hypothesis will be that, a) dm vs. non dm might have higher mortality rate after ca; b) patients with dm treated by ca plus slgt2 therapy vs. patients with dm treated by ca plus placebo might experience a lower rate of mortality at 1 year of follow-up. therefore, study aim will be to demonstrate a reduction of va, icds/crtds' interventions, and mortality in patients with dm treated by ca plus slgt2 therapy vs. patients with dm treated by ca plus placebo at 12 months of follow-up.

Eligibility criteria:
inclusion criteria: * heart failure (hf) under optimal maximal drug therapy with nyha functional ii-iii; * hf with prior echocardiographic evidence of left ventricular systolic dysfunction (lvef \<35 % or subjective assessment of lv dysfunction that is mild or worse); * patients under furosemide 80 mg daily or less, or equivalent loop diuretic; * patients with stable hf symptoms for at least 3 months prior to consent; * patients on stable therapy for hf for at least 3 months prior to consent; * patients without hospitalization for hf for at least 3 months prior to consent; * ischemic and non ischemic dilated cardiomiopathy diagnosis; * patients with internal cardioverter defibrillator (icd); * patients with cardioverter resynchronization therapy and defibrillator (crtd); * patients with diagnosis of diabetes mellitus (dm); * patients aged \>18 years and \<75 years exclusion criteria: * patients without icd; * patients without previous event of ventricular arrhythmia (va); * patients without indication to receive catheter ablation (ca) for va; * patients with type 1 diabetes mellitus; * severe hepatic disease, renal disease defined as chronic kidney disease stage 3b or worse (i.e. glomerular filtration rate \<45 ml/min); * systolic blood pressure \<95 mmhg at screening visit; * screening hba1c \<6.0 %; * patients unable to walk or to perform cardio pulmonary exercise testing or six minute walking test; * malignancy (receiving active treatment) or other life threatening diseases; * pregnant or lactating women; * patients who have participated in any other clinical trial of an investigational medicinal product within the previous 30 days; * patients who were unable to give informed consent; * any other reason considered by a study physician to be inappropriate for inclusion.